VPC-13789

• Description :

  VPC-13789 is a potent, selective, and orally bioavailable antiandrogen. VPC-13789 can be used for the research of castration-resistant prostate cancer (CRPC) therapeutics. VPC-13789 inhibits androgen receptor (AR) transcriptional activity in LNCaP cells (IC50=0.19 μM) [1].

• UNSPSC :

  12352005

• Target :

  Androgen Receptor

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cancer; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/vpc-13789.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C2C=CC(C3=CNC4=C3C=C(F)C(F)=C4F)=NC2=CC=C1)NC(C)C

• Molecular Formula :

  C21H16F3N3O

• Molecular Weight :

  383.37

• References & Citations :

  [1]Eric Leblanc , et al. Development of 2- (5,6,7-Trifluoro-1 H-Indol-3-yl) -quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. J Med Chem. 2021 Oct 28;64 (20) :14968-14982.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2761146-51-2]